Safe Prescribing of Valproate and Topiramate

Safe Prescribing of Valproate and Topiramate

This webinar will provide a practical update on the safe prescribing of valproate and topiramate, including:

·         A summary of the findings from the 2025/26 Medicines Incentive Scheme (MIS) audit.

·         An overview of the role and responsibilities of the named practice lead in supporting the safe use of these medicines as part of the 2026/27 MIS entry criteria.

·         Practical guidance on fulfilling MHRA requirements, with a particular focus on Annual Risk Acknowledgement Forms (ARAFs).